The OpTmizer CTS, as a human ex vivo (outside the body) tissue and cell culture processing application develops therapeutic T-cells to treat diseases including cancer, infectious diseases such as AIDS
As part of the agreement, Galderma will carry on the ongoing NVC-422 clinical development program for impetigo and NovaBay will receive double-digit royalties on net sales of products.
The once-daily investigational medicine FF/VI is used to treat chronic obstructive pulmonary disease (COPD). The Marketing Authorisation Application for FF/VI for COPD and asthma has also been validated
Teijin Pharma is planning to begin phase I clinical trials for ADC3680 in Japan in April 2013, while Pulmagen Therapeutics has already begun phase II clinical trials for
The company has already purchased land and is planning to begin the work from November 2012. The company will produce hi-tech Active Pharma Ingredients (APIs), specialty enzymes for
As part of the settlement, Abaxis will receive $17.25m from Cepheid and withdraw all pending litigation claims. Abaxis CEO and chairman Clint Severson said the agreement will allow
The added enhancements are available across all MedeAnalytics solutions and require no upgrades or installations to access them, according to the company. MedeAnalytic product management vice president Christian
RayBiotech will leverage the reagents and technologies to expand its antibody-based products and services platforms. The financial terms of the agreement were kept confidential. Commenting on the license,
The inspection involved a MHRA inspector who evaluated the facility and concluded that the site has no critical or major failures and continues to be compliant with EU
The companies are working to smoothly shift activities and make sure the continuous availability of the product in approved countries. Merck Research Laboratories atherosclerosis and cardiovascular research senior
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.